ERS 2026: Sanofi’s lunsekimig hits Phase IIb goals in asthma, Phase III set to follow
The data expands on a readout earlier this year when Sanofi revealed the trial had its primary endpoint.
The data expands on a readout earlier this year when Sanofi revealed the trial had its primary endpoint.